PRTA

9.21

1.07% -0.10

Handel nachbörslich: 9.21

Prothena Corporation Plc (PRTA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PRTA? Forum Prognose

Schlusskurs vom Vortag:

$9.31

Offen:

$9.4

24-Stunden-Volumen:

583.43K

Relative Volume:

1.03

Marktkapitalisierung:

$495.80M

Einnahmen:

$217.25M

Nettoeinkommen (Verlust:

$-50.92M

KGV:

-9.21

EPS:

-1

Netto-Cashflow:

$-100.85M

1W Leistung:

-3.96%

1M Leistung:

+2.79%

6M Leistung:

+12.18%

1J Leistung:

-34.54%

1-Tages-Spanne:

$8.995

$9.54

1-Wochen-Bereich:

$8.995

$10.27

52-Wochen-Spanne:

$4.32

$14.34

Prothena Corporation Plc Stock (PRTA) Company Profile

Firmenname

Prothena Corporation Plc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

011-353-1-236-2500

Adresse

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2

Mitarbeiter

Twitter

@ProthenaCorp

Nächster Verdiensttermin

2025-02-18

Neueste SEC-Einreichungen

PRTA's Discussions on Twitter

Compare PRTA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRTA Prothena Corporation Plc	9.21	501.19M	217.25M	-50.92M	-100.85M	-1.00
VRTX Vertex Pharmaceuticals Inc	469.34	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.65B	5.36B	287.73M	924.18M	2.5229

Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-28	Herabstufung	BofA Securities	Neutral → Underperform
2025-05-27	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-05-27	Herabstufung	Jefferies	Buy → Hold
2025-05-27	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Eingeleitet	Chardan Capital Markets	Buy
2024-01-30	Herabstufung	BofA Securities	Buy → Neutral
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-04-24	Eingeleitet	SVB Securities	Outperform
2023-01-27	Eingeleitet	Piper Sandler	Overweight
2022-11-04	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-09-28	Hochstufung	BofA Securities	Neutral → Buy
2021-11-19	Eingeleitet	JMP Securities	Mkt Outperform
2021-06-18	Hochstufung	BofA Securities	Underperform → Neutral
2021-06-08	Bestätigt	Oppenheimer	Outperform
2021-05-26	Eingeleitet	Citigroup	Buy
2021-02-26	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-02-12	Hochstufung	Jefferies	Hold → Buy
2021-02-02	Hochstufung	BTIG Research	Neutral → Buy
2020-12-07	Eingeleitet	H.C. Wainwright	Buy
2020-07-09	Hochstufung	Oppenheimer	Perform → Outperform
2019-11-19	Hochstufung	Evercore ISI	In-line → Outperform
2018-05-21	Herabstufung	Barclays	Equal Weight → Underweight
2018-04-23	Herabstufung	Jefferies	Buy → Hold
2018-04-05	Bestätigt	Barclays	Overweight
2017-11-20	Herabstufung	Wedbush	Outperform → Neutral
2017-09-29	Bestätigt	BTIG Research	Buy
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-07-11	Eingeleitet	Jefferies	Buy
2017-04-12	Eingeleitet	Cantor Fitzgerald	Overweight
2017-04-12	Eingeleitet	Piper Jaffray	Overweight
2017-03-02	Eingeleitet	Instinet	Buy
2016-12-21	Eingeleitet	SunTrust	Buy
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-08-04	Bestätigt	Barclays	Overweight
2016-05-13	Eingeleitet	Barclays	Overweight
2016-02-19	Bestätigt	Wedbush	Outperform
2016-01-21	Eingeleitet	Credit Suisse	Outperform

Alle ansehen

Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten

11:56 AM

Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS

11:56 AM

07:29 AM

Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS

07:29 AM

07:24 AM

Citizens reaffirms Prothena stock rating on Novo Nordisk milestone - Investing.com UK

07:24 AM

Mar 12, 2026

Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria

Mar 12, 2026

IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn

Mar 12, 2026

Mar 10, 2026

Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat

Mar 10, 2026

Mar 09, 2026

Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily

Mar 09, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com

Mar 09, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe

Mar 09, 2026

Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com

Mar 09, 2026

Mar 07, 2026

Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir

Mar 07, 2026

Mar 05, 2026

Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn

Mar 05, 2026

Mar 03, 2026

Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha

Mar 03, 2026

Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz

Mar 03, 2026

Mar 02, 2026

Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat

Mar 02, 2026

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 02, 2026

Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World

Mar 02, 2026

Mar 01, 2026

PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 01, 2026

Feb 27, 2026